Weight Loss

What to Look for in a Protein Powder?

Besides a balanced diet, many individuals opt to include supplements as part of their daily food intake. Protein powder is one such supplement which has become increasingly popular over recent years, with many users who want to achieve weight loss and muscle growth.

Mental Health Disorders, Weight Gain, and Exercise

GLP-1 and Diet: Evidence-Based Strategies for Better Weight Loss

Military Diet: Health Risks

Unexplained Weight Loss: When It Might Signal a Health Problem

Circadian Rhythm and Weight Loss

Is Cottage Cheese Good for Weight Loss? Evidence from Clinical Studies

Vegetarian Diets for Weight Loss

Cachexia / Wasting Syndrome

Does Cinnamon Help with Weight Loss?

Wegovy: A Breakthrough in Weight Loss?

Semaglutide and Weight Loss in Menopause

See more featured articles »

Is a Hypocaloric Diet Safe and Effective for Long-Term Health?

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

The Natural Molecule That Could Rival Ozempic

How Oral GLP-1 Drugs Work For Weight Loss

Cachexia and Cancer

Oral GLP-1 Pills for Weight Loss: How Orforglipron Works

Who Should Take Weight Loss Injections, and Who Shouldn’t?

How Does Semaglutide Work to Lose Weight?

Weight Loss After Bariatric Surgery

What Is Cancer Cachexia? Causes, Symptoms, Diagnosis, and Treatment

Latest Weight Loss News and Research

Digital companion apps help secure long-term habits during GLP-1 therapy

Glucagon-like peptide-1 (GLP-1) medications have revolutionized weight management, yet high dropout rates and rapid weight regain remain significant hurdles for many patients.

9 Sep 2026

Non-nutritive sweeteners may aid sugar reduction without affecting weight or health

The review, led by Eva Marija Čad of the University of Ljubljana and Wageningen University & Research, alongside Professor Graham Finlayson of the University of Leeds and colleagues from other institutions in the Netherlands, Denmark, Spain and Belgium, was developed in connection with a 2025 webinar series hosted by the Institute for the Advancement of Food and Nutrition Sciences (IAFNS).

9 Sep 2026

GLP-1 treatment linked to 40% fewer asthma attacks

The diabetes and weight loss injection semaglutide can reduce asthma attacks by up to 40 per cent according to research presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain.

7 Sep 2026

GLP-1 drugs looked promising for depression. The evidence tells a more complicated story

A systematic review of 43 studies found highly heterogeneous results for GLP-1 receptor agonists across animal models and human research assessing depression-, anxiety-, and stress-related outcomes. No study directly tested these drugs as a treatment for PTSD, and the available evidence does not currently support their use for depression or PTSD, although people with metabolic dysfunction may warrant further investigation.

7 Sep 2026

Bariatric surgery restores menstrual cycles and reduces polycystic ovaries in obese women

Metabolic bariatric surgery improves menstrual cycle frequency and symptoms of polycystic ovaries in women living with obesity, a new study from the University of Surrey reports.

7 Sep 2026

Dual-drug microneedle patch targets inflammation and fat browning

The worldwide obesity crisis has become a dominant public health crisis across the globe. Over 3 billion people worldwide currently suffer from obesity, and forecasts warn the number will rise above 4 billion by 2035, accounting for more than half the global population.

4 Sep 2026

Childhood obesity prescriptions for GLP-1 drugs surge in the U.S.

Although the number of US children under age 12 with obesity being prescribed the weight loss drugs Saxenda, Wegovy, and Zepbound remains low, the number is 310 times higher in June 2026 than it was in 2019, when the drugs were initially prescribed, a new study shows.

4 Sep 2026

What 107 professional MMA fighters actually ate before and after weigh-in

Professional UFC fighters followed highly structured dietary patterns around competition, sharply restricting carbohydrates, fiber, fluids, and sodium before weigh-in before rapidly increasing carbohydrate, fluid, and sodium intake afterward. Despite aggressive post-weigh-in refueling, carbohydrate intake fell again on fight day, suggesting that some fighters may not fully restore glycogen stores before competition.

3 Sep 2026

The obesity-microbiome story is more complicated than ‘good’ and ‘bad’ bacteria

This review finds that obesity is linked to reciprocal interactions between diet, the gut microbiome, microbial metabolites, and host metabolic pathways that influence appetite, insulin sensitivity, inflammation, and energy balance across the lifespan. It highlights diet as a particularly tractable way to influence this system, while emphasizing that microbiome changes associated with GLP-1 therapies remain difficult to separate from weight loss and that functional multi-omics approaches may help enable more personalized interventions.

3 Sep 2026

Study links popular weight-loss drugs to increased male hair loss

Men already at risk genetically for the most common form of hair loss have a 7 percent added risk of losing their hair if they use drugs like Ozempic, Wegovy, and Zepbound for type 2 diabetes and obesity, a new study shows.

3 Sep 2026

Researchers identify a previously unknown mechanism that can drive cancer cachexia

Researchers at Helmholtz Munich, the Heidelberg Faculty of Medicine at Heidelberg University, the German Center for Diabetes Research (DZD) and the Technical University of Munich (TUM), have identified a previously unknown mechanism that can drive cancer cachexia – a wasting process in the body that primarily affects muscle and fat tissue.

1 Sep 2026

Study identifies three distinct BMI trajectories among people with type 2 diabetes

A recent study by the University of Eastern Finland identified three distinct body mass index (BMI) trajectories among people with type 2 diabetes.

1 Sep 2026

GLP-1 drugs have benefits beyond weight loss. Could microdoses preserve them?

A narrative review suggests GLP-1-based therapies deliver metabolic, cardiovascular, renal, and other systemic benefits, raising interest in whether lower fractional doses could improve tolerability and treatment continuity. However, direct evidence for GLP-1 microdosing remains extremely limited, and researchers say prospective studies are needed to determine whether lower doses preserve long-term benefits.

1 Sep 2026

Semaglutide did more than cut weight in this analysis of 6,239 adults

A systematic review and meta-analysis of nine randomized controlled trials involving 6,239 adults with overweight or obesity without diabetes found that subcutaneous semaglutide produced substantially greater reductions in body weight, waist circumference, and C-reactive protein than placebo. The higher dose of 7.2 mg semaglutide showed potential for greater weight loss, although the evidence is largely based on a single trial and requires confirmation.

31 Aug 2026

New dual-drug strategy blocks triple-negative breast cancer growth

Triple-negative breast cancer (TNBC) has a frustrating ability to adapt. Although this aggressive form of breast cancer can initially respond well to chemotherapy, cancer cells often find ways to survive, allowing the disease to return and become resistant to treatment.

31 Aug 2026

The scale told a similar story across three diets. The liver told a different one

In a randomized controlled trial of people with metabolically unhealthy obesity, approximately 10% weight loss improved insulin sensitivity and several cardiometabolic measures across ketogenic, Mediterranean, and very-low-fat plant-forward diets. However, the very-low-carbohydrate ketogenic diet produced larger improvements in hepatic insulin sensitivity and greater reductions in liver fat and several glucose and insulin measures than the higher-carbohydrate diets.

31 Aug 2026

Experts call for safer weight loss as concerns grow over GLP-1 use

An editorial in Diabetology International argues that inappropriate GLP-1 use should be judged not only by regulatory compliance or off-label prescribing, but also by whether weight reduction is medically safe, nutritionally adequate, and properly supervised. Drawing on Japanese reports of ketosis and ketoacidosis following inappropriate tirzepatide use, the authors call for greater attention to the risks of unsafe weight-loss practices alongside medication-related harms.

30 Aug 2026

Is there a best day to take GLP-1 drugs? Researchers looked for an answer

A systematic review of 1,000 screened records identified only three eligible studies examining administration timing for semaglutide, and none directly compared different days of the week or assessed tirzepatide timing. The limited evidence suggests flexible dosing may support adherence and tolerability without compromising glycemic control or weight loss, but these findings rely largely on indirect evidence and expert opinion rather than direct comparative trials.

30 Aug 2026

Researchers identify early molecular warning signs of inflammatory bowel disease

Researchers have uncovered early molecular warning signs of inflammatory bowel disease, revealing the condition can begin before symptoms appear and continue silently even when patients appear well.

From Walter and Eliza Hall Institute of Medical Research (WEHI) 29 Aug 2026